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Exome sequencing in families affected by rare genetic disorders has the potential to rapidly identify new disease genes (genes in which
mutations cause disease), but the identification of a single causal mutation among thousands of variants remains a significant challenge.
We developed a scoring algorithm to prioritize potential causal variants within a family according to segregation with the phenotype,
population frequency, predicted effect, and gene expression in the tissue(s) of interest. To narrow the search space in families with
multiple affected individuals, we also developed two complementary approaches to exome-based mapping of autosomal-dominant
disorders. One approach identifies segments of maximum identity by descent among affected individuals; the other nominates regions
on the basis of shared rare variants and the absence of homozygous differences between affected individuals. We showcase our methods
by using exome sequence data from families affected by autosomal-dominant retinitis pigmentosa (adRP), a rare disorder characterized
by night blindness and progressive vision loss. We performed exome capture and sequencing on 91 samples representing 24 families
affected by probable adRP but lacking common disease-causing mutations. Eight of 24 families (33%) were revealed to harbor high-scor-
ing, most likely pathogenic (by clinical assessment)mutations affecting knownRP genes. Analysis of the remaining 17 families identified
candidate variants in a number of interesting genes, some of which have withstood further segregation testing in extended pedigrees.
To empower the search for Mendelian-disease genes in family-based sequencing studies, we implemented them in a cross-platform-
compatible software package, MendelScan, which is freely available to the research community.Introduction
High-throughput-sequencing (HTS) technologies hold
incredible promise for uncovering the genetic basis of
human disease, particularly for rare inherited condi-
tions. Sequencing the exons of all known protein-coding
genes—the exome—offers a powerful approach to rapidly
screening for candidate disease-causing mutations in cod-
ing regions.1 Early applications of exome sequencing to
rare Mendelian disorders demonstrated that it was possible
to identify new disease genes (genes in which mutations
cause disease) by sequencing the exomes of just a few un-
related individuals2–6 or family members.7–13 For many
disorders, however, pinpointing the responsible mutation
or associated gene by exome sequencing remains chal-
lenging. Each individual harbors thousands of coding var-
iants, of which a significant fraction (~5%–10%) are absent
from public databases such as dbSNP14 or have no allele
frequency data. The genomes of healthy individuals
contain ~100 loss-of-function variants,15 further compli-
cating the identification of disease-causing mutations.
To date, exome sequencing studies of rare inherited
disorders have generally used a winnowing strategy in
which variants are progressively filtered for removal of
those deemed unlikely to cause disease.1 Current statistical
frameworks16,17 and analytic tools such as KGGSeq,18
VAAST,19 and VAR-MD20 filter and prioritize variants on
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The Ameinformation, and genotype quality. Despite some successes,
a strict filtering approach carries certain risks. Incomplete
penetrance, genetic heterogeneity, and incorrect pedigree
information21 can hamper segregation analysis. Rare and
disease-causing variants are increasingly represented in
dbSNP and other databases. Further, the complexity of the
human transcriptome hampers accurate prediction of a
sequence variant’s probable effect at the molecular level in
the tissue(s) of interest.22
To aid the analysis of sequencing data from families
affected by rare disorders, we developed a strategy for
prioritizing genetic variants on the basis of segregation
with disease, prevalence in human populations, predicted
annotation, and the relative expression of the affected
gene in the tissue(s) of interest. To further narrow the
search for disease genes, we also developed two comple-
mentary approaches for identifying regions consistent
with a disease-causing haplotype. We showcase our
methods on exome data from families affected by retinitis
pigmentosa (RP [MIM 268000]), a heterogeneous group of
inherited retinal degenerations characterized by night
blindness and progressive vision loss.23 Nearly 3,100muta-
tions in more than 50 different genes have been reported
to cause nonsyndromic RP,24 but these genes account for
only ~60% of affected individuals, suggesting that many
genes have yet to be discovered.25
In eight of our 24 families (29%), we found a pathogenic
variant segregating with disease in a known RP gene. AllumanGenetics Center, University of Texas Health Science Center, Houston,
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Table 1. Families Selected for Exome Sequencing from a Cohort of
Families Affected by adRP or Dominant-Acting X-Linked RP but
Lacking Common Mutations
Family ID Ethnicity
Affected
Individuals
Sequenced
Unaffected
Individuals
Sequenced
Total
Samples
Sequenced
ADRP01 white 2 0 2
ADRP02 black 5 0 5
ADRP03 white 3 1 4
ADRP04 white 2 0 2
ADRP05 white 3 0 3
ADRP06 Hispanic 3 0 3
ADRP07 white 3 1 4
ADRP08 black 7 1 8
ADRP09 white 3 1 4
ADRP10 white 2 0 2
ADRP11 white 2 0 2
ADRP12 white 3 0 3
ADRP13 white 2 1 3
ADRP14 white 3 0 3
ADRP15 white 4 1 5
ADRP16 white 5 2 7
ADRP17 Hispanic 2 0 2
ADRP18 white 2 1 3
ADRP19 Hispanic 2 0 2
ADRP20 white 6 0 6
ADRP21 white 3 1 4
ADRP22 white 3 1 4
ADRP23 white 6 2 8
ADRP24 white 2 0 2
Numbers reflect the samples that underwent exome sequencing. One family
(ADRP12) received a provisional diagnosis of X-linked RP; the rest were provi-
sionally diagnosed with adRP.eight causal mutations were among the top-scoring vari-
ants in those respective families, despite the fact that
some proved to be X-linked (two families) or recessive
(CNGB1 [MIM 600724]) forms of the disease. Several fam-
ilies had known linkage regions from traditional linkage
analysis of extended pedigrees, and all of these regions
were successfully recapitulated by our methods for map-
ping disease genes. Taken together, our methods provide
a powerful analysis framework for exome sequencing
of rare Mendelian disorders, and we make them freely
available in the software package MendelScan.Subjects and Methods
Subjects
A subset of 24 families was selected from a previously described
cohort of 230 families affected by autosomal-dominant RP374 The American Journal of Human Genetics 94, 373–384, March 6(adRP).26,27 The families were chosen on the basis of pedigree anal-
ysis, a lack of common RP-causing mutations, and the availability
of DNA (Table 1). Within each family, individuals were chosen ac-
cording to affectation status (two to seven affected individuals and
zero to two controls per family), kinship coefficient, availability of
DNA, and sample consent. Only unaffected parents of probands
(noncarriers) were chosen as controls. In total, 91 individuals
were selected for exome sequencing (Table S1, available online).
This research adhered to the tenets of the Declaration of Hel-
sinki. Informed consent was obtained from each of the individuals
tested. This study was approved by the Committee for the Protec-
tion of Human Subjects of the University of Texas Health Science
Center at Houston and by the respective human subjects’ review
boards at each of the participating institutions.
Sample Preparation
DNA was extracted from blood with the use of either the QIAamp
DNA Blood Kit or the Gentra Puregene Blood Kit (QIAGEN). DNA
was subjected to whole-genome amplification (WGA) by QIAGEN’s
REPLI-g genome amplification service. Only WGA DNAs with
assessment ratings indicating a >99% accuracy rate were used.
Illumina paired-end libraries were made from 1 mg of DNA ac-
cording to the manufacturer’s protocol with slight modifications:
(1) DNA was fragmented into sizes ranging from 100 to 500 bp
with a Covaris S2 DNA Sonicator (Covaris), (2) Illumina adaptor-
ligated DNA was amplified in a single 50 ml PCR reaction for five
cycles, and (3) solid-phase reversible immobilization bead cleanup
was used for purifying the PCR amplification and selecting frag-
ments 300–500 bp in size.
Exome Capture
Sequencing libraries were hybridized with either a customized Agi-
lent SureSelect All Exome Kit v.2.0 (Agilent Technologies) or the
NimblegenSeqCapEZHumanExomeLibraryv.2.0 (seeTable S1) ac-
cording to themanufacturers’ protocol. The KAPA SYBR FASTqPCR
Kit (KAPA Biosystems) was used for library quantification. Libraries
were quantified with PicoGreen prior to paired-end sequencing
(23 100 bp) on Illumina GAIIx or HiSeq2000 instruments.
Sequence Alignment and Variant Calling
Illumina reads passing instrument quality control were aligned
to the GRCh37-lite reference sequence with the Burrows-Wheeler
Aligner28 v.0.5.9; parameters ‘‘–t 4 –q 5’’ were passed to the ‘‘bwa
aln’’ command, and defaults were used for other commands. Dupli-
catesweremarkedbyPicardv.1.46. Single-nucleotidevariants (SNVs)
were called with VarScan v.2.2.9 (with parameters ‘‘--min-coverage
3 --min-var-freq 0.20 --p-value 0.10 --strand-filter 1 --map-quality
10’’) and SAMtools v.0.1.16 and filtered for removal of false positives
as previously described.29 Small indelswere calledbyVarScanv.2.2.9
with the same parameters and false-positive filtering.
Variant Compilation and Annotation
For each family, cross-sample variant call format (VCF) files were
generated for each variant type (SNVs and indels). Sites that failed
the false-positive filter in >50% of samples in the family were
removed as probable artifacts. Missing genotypes were backfilled
via SAMtools consensus calling (samtools pileup –c). Variants
were annotated with information from the dbSNP build 137
VCF file with the ‘‘vcf-annotate’’ command of the JoinX tool
(v.1.6). Known dbSNP variants in the VCF were updated with a
reference SNP ID in the ID column and global minor allele, 2014
frequency (GMAF) and mutation status (in PubMed, OMIM, or
locus-specific databases [LSDBs]) in the INFO column.
Variants were also annotated with gene-structure informa-
tion with the use of internal software (and Ensembl release 70)
and the Variant Effect Predictor (VEP) v.2.2 with parameters
‘‘--condel b --polyphen b --sift b --hgnc --canonical.’’ For each
gene, the canonical VEP annotation was used whenever possible.
In the event of multiple overlapping genes that yielded different
annotations, the most damaging annotation was used. In coding
regions, the priority order (from most damaging to least
damaging) was the following: frameshift, nonsense, essential
splice site, missense, nonstop, synonymous coding. Missense var-
iants were considered damaging if called as such by at least one of
PolyPhen (‘‘probably_damaging’’ or ‘‘possibly_damaging’’), SIFT
(‘‘deleterious’’), or Condel (‘‘deleterious’’).Segregation-Score Parameter Analysis
To help choose appropriate default values for the segregation
score, we obtained the genotypes for a mother-father-child trio
from the VCF file for family ADRP22. Only biallelic SNVs with a
read depth of at least 20 in all three samples were considered.
There were 6,539 positions at which parents were homozygously
different (i.e., one parent was wild-type and the other was homo-
zygous for variants) and thus the child should have been heterozy-
gous. Of these, the child was called wild-type at 159 positions and
homozygous for variants at 91 positions. Thus, we estimated the
false-negative rate to be 159/6,539 (2.43%) and the miscall rate
to be 250/6,539 (3.8%). Of the 37,021 positions at which the child
was called heterozygous, 340 were called wild-type in both par-
ents. Thus, we estimated the false-positive rate to be 340/37,021
(0.92%).
To be conservative, we chose scoring parameters reflecting
80% sensitivity to detect heterozygotes (observed sensitivity was
97.57%). A variant appearing to be wild-type in an affected
individual thus received a segregation score of 0.20. Similarly, we
scored a variant that was heterozygous in a control with the
conservative false-positive rate of 5% (segregation score 0.05).
Although the miscall rate (heterozygotes mistaken for homozy-
gotes) was only 3.8%, it is possible that even rare variants could
have been present in two copies in an affected individual (either
by chance or from a distantly consanguineous union). Thus, we
allowed ~20% of apparent homozygous variants in affected indi-
viduals to be either real or a miscalled heterozygote (segregation
score 0.20).MendelScan Software Implementation
Variant prioritization, shared identity-by-descent (IBD) mapping,
and rare-heterozygote-rule-out (RHRO) mapping were imple-
mented in the Java software packageMendelScan. Required inputs
for MendelScan include (1) a VCF file comprising variant calls for
all sequenced samples from a family, (2) a pedigree file indicating
the gender and affectation status of each sample, and (3) annota-
tion information in VEP format for the variants in the VCF file.
The shared-IBD (SIBD) analysis also requires BEAGLE FastIBD
(FIBD) files for all affected pairs within a family.Ingenuity Variant Analysis
The eight families affected by known pathogenic mutations were
also analyzed with Ingenuity Variant Analysis (IVA) software.
SNVs were uploaded in VCF format via the web-based interface.
One analysis (of type ‘‘genetic analysis’’ with inheritance modelThe Ame‘‘autosomal dominant’’ and phenotype ‘‘retinitis pigmentosa
[disease]’’) was created for each family. Affected or unaffected sta-
tus for each sample was specified. Because pedigree information
was not available for most of these families, it was not provided
to IVA. Otherwise, the default settings were used. For two families
affected by CHM (MIM 300390) mutations, we repeated the anal-
ysis after adding ‘‘choroid degeneration [disease]’’ as a phenotype
and selected the ‘‘included phenotypes consistent with this
disease’’ option.IBD Analysis
To identify regions of maximum pairwise IBD between affected in-
dividuals in a family, we converted family VCF files to the BEAGLE
unphased genotype file format. Genetic-map positions were inter-
polated from the International HapMap Project Phase II genetic
map (liftOver to build 37, dated August 12, 2010). IBD regions
were determined between all possible affected pairs in a family
with the use of BEAGLE v.3.3.12 with ‘‘fastibd ¼ true.’’ The result-
ing files (*.fibd) were mapped back to genomic coordinates. Next,
the genome was segmented into nonoverlapping windows of
100 kb. For each window, the total number of unique affected
pairs with a segment in common (IBD score < 10 3 1010) was
computed with FIBD output.RHRO Analysis
The RHROmethodology relies on the assumption that all affected
individuals within a family inherited the same causal mutation
from a common ancestor. To identify regions consistent with auto-
somal-dominant disease inheritance, we scanned family VCFs for
(1) presumably rare variants (absent from dbSNP 137) that were
heterozygous in affected individuals and (2) homozygous differ-
ences between affected individuals in a family. Common variants
(present in dbSNP 137) with homozygous differences between
affected individuals were included. Only variants called in at least
50% of sequenced samples in a family were used for this analysis.
A sliding-window approach identified candidate RHRO regions in
which one or more rare heterozygous variants were shared by
100% of affected individuals called. A window began at the first
such shared rare variant and extended until a homozygous differ-
ence, the centromere, or the end of the chromosome was reached.Results
We set out to develop a scoring system to prioritize candi-
date variants in family-based sequencing studies of Men-
delian disease. Our strategy relies on the expectation that
disease-causing mutations in such studies will be pene-
trant, meaning that they segregate with the phenotype as
expected for themodel of inheritance. Evolutionary theory
further suggests that variants responsible for inherited dis-
ease should be selected against; thus, we expect them to
be rare among human populations. Although we admit
that regulatory variants in noncoding sequences might
contribute to disease, we expect that the vast majority of
disease-causing mutations alter the sequence of proteins
by disrupting coding sequences, splicing, or translation.
In particular, the disease-causing mutations detected by
exome sequencing seem likely to occur in the coding
sequences targeted by this strategy. Finally, we anticipaterican Journal of Human Genetics 94, 373–384, March 6, 2014 375
Figure 1. Summary of 762 Mutations Re-
ported to Cause adRP or Dominant-Acting
X-Linked RP
(A) Status according to dbSNP 137. dbSNP
variants with GMAF values were classified
as common (GMAF > 5%), uncommon
(GMAF 1%–5%), or rare (GMAF < 1%).
Otherwise, they were classified either as a
mutation if they were present in OMIM or
a LSDB or as simply known to dbSNP but
lacking frequency information (‘‘known’’).
(B) Annotation class of causal mutations.
The most damaging VEP classification
for the canonical transcript was used. The
‘‘splice region’’ category includes annota-
tions for essential splice sites, splice sites,
and splice regions.
(C) Predicted impact of nonsynonymous
mutations by PolyPhen, SIFT, and Con-
del. VEP results for 454 nonsynonymous
SNVs were categorized by the number of
algorithms that deemed the variant to be
deleterious.
(D) Gene expression scores were computed
as the relative rank (percentile, see Subjects
and Methods) of genes by maximum
(y axis) or mean (x axis) expression values
from the Farkas et al.31 human retina
RNA-seq data set. Genes in which muta-
tions are reported to cause retinal disease
(RetNet) are colored in blue; the subset
(n ¼ 23) of these reported to cause adRP
are colored in red.that the genes associated with Mendelian diseases are nor-
mally expressed in the tissue(s) of interest, an expectation
supported for retinal-disease genes in recent transcriptome
studies of murine30 and human31 retina samples.
Evaluation of Disease-Causing Mutations
To evaluate these expectations, we examined mutation
and gene expression data sets for genes already implicated
in adRP. We downloaded mutations for the 23 known
genes associated with adRP or dominant-acting X-linked
RP in the Human Gene Mutation Database (HGMD, ac-
cessed June 17, 2013) and found 762 mutations (632
SNVs and 130 indels) reported to cause adRP or domi-
nant-acting X-linked RP. Consistent with our expectations,
these mutations were extremely rare; 523 (68.3%) were
novel to dbSNP 137, and another 160 (21.0%) were only
reported by mutation databases (Figure 1A). When classi-
fied by current VEP annotation, most of the mutations
were predicted to alter protein sequence (66%), reading
frame (13.5%), splicing (4.3%), or length (6.8%); only 46
(6%) were annotated as synonymous or noncoding muta-
tions (Figure 1B). Among 454 nonsynonymous SNVs as-
sessed by PolyPhen, SIFT, and Condel, there were 417
(92%) predicted to be damaging by at least one algorithm
and 341 (75%) predicted to be damaging by all three
(Figure 1C).
Next, we downloaded human retinal expression data
generated by transcriptome sequencing (RNA-seq) of three376 The American Journal of Human Genetics 94, 373–384, March 6normal postmortem retina samples. We computed both
the maximum and the mean retinal expression in reads
per kilobase per million (RPKM, see Subjects and Methods)
for every gene in our database (Figure 1D). Consistent with
previous studies, most genes associated with retinal dis-
ease in humans (RetNet) were highly expressed in the
retina; of the 207 RetNet genes with expression data, 151
(73%) were in the top quadrant of retinally expressed
genes and 200 (96.6%) were in the top half. The subset of
genes associated with adRP or dominant-acting X-linked
RP (n ¼ 23) followed this trend as well; all were in the
top half of retinally expressed genes, and 19 (83%) were
in the top quadrant. Because many genes have retina-spe-
cific transcripts, we used the maximum RPKM value
to rank genes for all subsequent analyses. RHO (MIM
180380), which encodes the rhodopsin pigment and in
which mutations account for 30%–40% of individuals
with adRP, was the fifth-highest retinally expressed gene
by this measure.
Scoring System for Candidate Variants
Our analysis of known mutations in adRP or dominant-
acting X-linked RP demonstrated that the vast majority
of causal mutations are extremely rare protein-altering var-
iants in genes with high retinal expression. We therefore
implemented a scoring system for variants obtained by
family-based exome sequencing of Mendelian disorders;
in this system, each variant receives four individual scores, 2014
(each between 0 and 1) on the basis of segregation with the
phenotype, prevalence in human populations, annota-
tion, and expression in tissue(s) of interest:
1. The segregation score is based upon segregation with
disease in the family and accounts for the possibility
of sequencing or genotyping error. For rare auto-
somal-dominant disease, we expect all affected indi-
viduals in a family to be heterozygous for the causal
mutation, which should be absent from the unaf-
fected controls. Under this dominant model for
rare disease, a pathogenic mutation’s deviation
from the expected segregation must be artifactual.
We selected initial values for scoring on the basis of
a conservative view of next-generation-sequencing
accuracy: 80% sensitivity, 5% false-positive rate,
and 20% miscall rate (heterozygous variants called
homozygous). Thus, we assigned a score of 0.80 to
a variant if it was homozygous in an affected individ-
ual (1  miscall rate), 0.20 if it was absent from
an affected individual (1  sensitivity), or 0.05 if it
was present in a control (false-positive rate) (Table
S2). These values are completely configurable by
the user; our default settings derive from an analysis
of a family trio (see ‘‘Segregation-Score Parameter
Analysis’’ in the Subjects and Methods). We also
allow the user to specify a sequencing-depth
threshold (default is 20) below which variants are
treated as missing data. Affected individuals who
are called wild-type despite some evidence of a
variant (default is 5% of reads) are also treated as
missing data.
2. The population score indicates the variant’s rareness
among population cohorts, such as the 1000
Genomes panels. Information fields for GMAF from
the 1000 Genomes Project, citations in PubMed,
and status in OMIM or LSDBs are used for deter-
mining a variant’s population-frequency status
as either common (GMAF > 5%), uncommon
(GMAF ¼ 1%–5%), rare (GMAF < 1%), known (no
GMAF available), mutation (in PubMed, OMIM, or
LSDBs), or novel to dbSNP. Because adRP or domi-
nant-acting X-linked RP is rare in human popu-
lations, in our analysis we assigned very low
population scores to dbSNP variants with GMAF
data (0.001 for common variants, 0.02 for uncom-
mon variants, and 0.20 for rare variants), high scores
for variants that were novel (1.00) or listed as ‘‘muta-
tion’’ (0.95) in dbSNP, and moderate scores for other
dbSNP variants (0.60) (see Table S2). These values can
and should be adjusted for studies with different dis-
ease prevalence or modes of inheritance.
3. The annotation score reflects the predicted functional
impact of the variant on the encoded gene. Each
variant is assigned an annotation score on the basis
of the most damaging canonical VEP annotation.
Given the observation that most known disease-The Amecausing mutations in adRP or dominant-acting
X-linked RP alter protein structure, we assigned the
highest annotation scores to truncating (1.00) and
essential splice-site (1.00) variants. Missense variants
were scored as 0.95 if found to be damaging by Poly-
Phen, SIFT, or Condel or 0.80 if predicted to be
benign. Lower scores were given to variants in the
intronic splice region (0.20), synonymous coding
variants (0.05), and noncoding variants (0.01).
4. The gene expression score is based upon the relative
expression of the gene in tissue(s) of interest for
the disease. The gene expression values are provided
to MendelScan as a text file containing HUGO gene
symbols ordered from highest relevance (expression)
to lowest. Variants in genes that are not included in
the expression file receive essentially a neutral score
(0.50), whereas highly expressed genes receive a
score closer to 1 and genes with relatively low expres-
sion receive a score closer to 0. Retinal expression is
of keen interest for RP, so we obtained human retinal
expression values for genes by using a public data set
of RNA-seq from three normal retinal samples. The
gene expression score was computed as the rank
percentile of each gene (1 rank/total). For example,
the gene encoding rhodopsin (RHO) was ranked fifth
overall for retinal expression, so its gene expression
score was 0.99987.
The score assignments are completely configurable
by MendelScan users; for demonstration purposes, we
selected values appropriate for adRP, and these are outlined
in Table S2. An overall score, computed from the product
of the four individual scores, makes it possible to sort var-
iants according to their segregation with the phenotype,
rareness in populations, predicted functional impact, and
expression in the tissue(s) of interest.
Application of Methods to Sequencing Data from
adRP-Affected Families
We performed exome sequencing on 91 individuals from
24 families affected by adRP or dominant-acting X-linked
RP (Table 1). Illumina sequencing libraries underwent
exome capture with either Agilent or Nimblegen kits and
were sequenced on GAIIx or HiSeq2000 instruments (see
Subjects and Methods and Table S1). We generated ~14.4
Gb of sequence per individual; 98% of targeted bases
were covered by at least one read, and ~89% were covered
by at least 20 reads. On average, our variant-calling pipe-
line identified ~30,000 SNVs per individual in targeted
coding sequences (~34 Mb), and >98% of these were pre-
sent in dbSNP build 137 (Figure 2A). As expected, more
SNVs were called relative to the reference sequence in
families of African ancestry than in families of European
ancestry. Similar patterns were observed for small indels:
~600 variants were called per family in coding-sequence
regions, and ~81% of these were present in dbSNP 137
(Figure 2B). The number of variants novel to dbSNP rangedrican Journal of Human Genetics 94, 373–384, March 6, 2014 377
Figure 2. Variants Called per Family in CDS Regions by Ethnicity
and Number of Exomes Sequenced
The total number of variants known (blue) or novel (red) to dbSNP
137 is shown for each of the 24 families chosen for exome
sequencing.
(A) SNVs: ~29,784 per family and 98% known to dbSNP.
(B) Indels: ~605 per family and 81% known to dbSNP.from ~400 in white families with just two sequenced mem-
bers to more than 2,500 in an eight-member family of
African American descent.
Eight of 24 families harbored rare mutations in known
RP genes (Table 2). Notably, two of these were nonsense
mutations in the X-linked gene CHM, consistent with
our previous observation that X-linked genes account for
a significant fraction of families with a provisional diag-
nosis of adRP.21 Another family with presumed X-linked
inheritance was actually affected by recessive disease; the
pathogenic mutation in CNGB1 (MIM 600724) still ranked
in the top 2% of candidate SNVs (when sorted by overall
score) and highlighted an error in the pedigree. For the
remaining seven families, the causal mutation consis-
tently appeared among top-scoring variants (on average,
it ranked fifth).
To compare our results with those of a popular filter-
based tool, we analyzed these eight families with the
web-based IVA. For each family, we uploaded the VCF file
for SNVs and specified a genetic analysis for ‘‘retinitis pig-
mentosa [disease]’’ with autosomal-dominant inheritance.
IVA progressively filters variants on the basis of confidence
of the variant calls, prevalence in human populations, pre-
dicted deleteriousness, and biological context by using a
proprietary database. Using the default settings, IVA pro-
duced a final list of ~25 variants affecting six to seven genes
in each family (Table S3). In four families (50%), the final
set included the causal mutation. In two families (25%),
the causal mutation was removed at the last step (biolog-378 The American Journal of Human Genetics 94, 373–384, March 6ical context) unless related phenotypes (choroid degenera-
tion) were provided. In two families (25%), the causal
mutation was deemed neutral by SIFT and thus removed
by the ‘‘deleterious’’ filter (Table S4). Taken together, these
results suggest that filtering methods are effective for first-
pass analysis of Mendelian-disease studies but that a prior-
itization strategy such as ours might be more robust to
errors in the presumedmode of inheritance or in silico pre-
diction of variant pathogenicity.
Exome-Based Mapping for Autosomal-Dominant
Disorders
To further refine the search for disease-causing mutations,
we also developed two methods for exome-based disease-
gene mapping in families with autosomal-dominant dis-
ease inheritance. Both methods aim to identify genomic
regions that are shared by affected family members and
that might harbor the disease-causing allele, and they
thus require family cohorts with at least two affected indi-
viduals. For the first method, called RHRO, we reasoned
that a rare causative mutation probably segregates on the
same haplotype as do other rare variants that are nearby
but do not cause disease. In other words, if all affected
members of a family inherit the causal mutation from a
common ancestor, that mutation lies on a haplotype that
might contain other variants that also segregate with dis-
ease. We also reasoned that homozygous differences
between two affected individuals indicate positions where
the samples have no haplotype in common. Thus, the
genomic region harboring the disease-causing mutation
should contain rare heterozygous variants shared by all
affected individuals but should not contain variants with
homozygous differences between affected individuals
(Figure 3).
For the second method, called SIBD, we attempt to
identify regions inherited by all affected individuals in a
family from a common ancestor. First, we compute the
pairwise IBD between every possible affected pairing in a
family by using the FIBD algorithm in BEAGLE. Next, we
divide the genome into segments of a fixed size (100 kb)
and compute the number of affected pairings that are
identical by descent within that segment. To allow for
some incomplete IBD estimation, we consider windows
in which R80% of possible affected pairings show IBD to
be SIBD candidate regions.
We applied both exome-based disease-gene mapping
methods to the 15 families in which at least three affected
individuals were sequenced. Three such families already
had candidate linkage regions (Table 3) from traditional
SNP or short-tandem-repeat genotyping in the extended
pedigrees (S.H.B., data not shown), allowing a direct com-
parison of our methods to the results of traditional
approaches. The results for family ADRP16 (five affected
individuals) are shown in Figure 4. Our mapping ap-
proaches supported four striking candidate regions, two
of which overlapped the known linkage regions on chro-
mosomes 15 and 19 (Figure S1). A number of smaller, 2014
Table 2. Families Harboring Most Likely Pathogenic Mutations in Known adRP Genes
Family ID Presumed Inheritance Exomes (No. Affected) Gene (MIM Number) Rank (Total SNVs) Actual Inheritance
ADRP04 dominant 2 (2) SNRNP200 (601664) 1 (25,418) dominant
ADRP06 dominant 3 (3) CHM (300390) 13 (28,395) X-linked
ADRP09 dominant 4 (3) CHM (300390) 4 (33,785) X-linked
ADRP11 dominant 2 (2) PROM1 (604365) 2 (23,729) dominant
ADRP12 X-linked 3 (3) CNGB1 (600724) 439 (26,666) recessive
ADRP18 dominant 3 (2) NRL (162080) 2 (25,604) dominant
ADRP21 dominant 4 (3) SNRNP200 (601664) 1 (33,072) dominant
ADRP22 dominant 4 (3) RPE65 (180069) 12 (27,573) dominant
The number of samples (and number affected) is shown. Rank by overall score and presumed versus actual mode of inheritance are shown.regions on other chromosomes were supported by
only one of our methods, suggesting that taking the inter-
section of RHRO and SIBD results yields more robust map-
ping by incorporating information from rare and common
variants. In family ADRP23 (six affected individuals), our
results were consistent with linkage data for three chromo-
somes (2, 4, and 18) while nominating regions on four
others. In our most informative family, ADRP08 (seven
affected individuals), both traditional linkage analysis
and our exome-based analysis implicated an almost iden-
tical region on a single chromosome (19).
As expected, our methods were most powerful for fam-
ilies in whichmany affected individuals from the extended
pedigree were sequenced. In families with four or more
affected individuals, our methods refined the search space
to 5% or less of the targeted coding sequence (Table 4). For
families with three affected individuals, the intersection of
RHRO and SIBD candidate regions overlapped roughly half
of the ~33 Mb targeted coding sequence. On average, per
family, we observed ~810 SNVs that fit an autosomal-
dominant model of inheritance and were rare in human
populations (Table S5); of these, 634 (78.3%) were sup-
ported by at least one mapping method and 384 (47.4%)
were supported by both methods. In two such families,
exome sequencing uncovered a pathogenic mutation in
known RP genes: SNRNP200 (MIM 601664) in family
ADRP2132 and RPE65 (MIM 180069) in family ADRP22.33
In both cases, our disease-gene mapping methods nomi-
nated candidate regions overlapping the location of the
causal mutation (Figure S2).
The MendelScan Software Package
We implemented our analysis methods in a standalone
software package (MendelScan) that is freely available to
the research community. Although the default scoring
thresholds reflect our experience with rare, autosomal-
dominant disorders, we designed MendelScan to be highly
configurable so that it can be used for studying other types
of inherited disease. Source code, executables, and docu-
mentation for the software package are available on the
MendelScan web site.The AmeDiscussion
We have described variant prioritization and disease-gene
mapping strategies that empower the search for Mende-
lian-disease genes in family-based sequencing studies.
Motivated by population-genetics theory and empirical
observations of rare disease-causing mutations in adRP,
we devised a strategy to prioritize candidate sequence var-
iants on the basis of their segregation patterns within a
family, prevalence in surveyed human populations, and
predicted functional impact, along with the relative
expression of the affected gene in tissue(s) of interest.
Further, we reasoned that causal mutations inherited
from a common ancestor in dominant pedigrees would
give rise to certain patterns—regions of IBD, clusters of
shared rare variants, and an absence of homozygous differ-
ences among affected individuals—that can be detected
with exome data and exploited for disease-gene mapping.
We have showcased our methods by using exome data
from 24 families with a provisional diagnosis of adRP
(n ¼ 23) or X-linked RP (n ¼ 1) but without common dis-
ease-causing mutations. Per family, our variant detection
and annotation pipelines identified ~400–2,500 rare
sequence variants that might be candidate causal muta-
tions, demonstrating the need for rational prioritization
strategies in exome studies of rare disease. Popular filtering
strategies, such as those employed by IVA, efficiently
reduce the list of candidate variants to a small number
but are vulnerable to inaccurate pedigree information
and errors in in silico predictions of variant pathogenicity.
In our study, eight families harbored likely causal muta-
tions in known RP genes, and all of them were ranked in
the top 2% of variants by our prioritization strategy.
Notably, this included two families affected by X-linked
RP and another affected by recessive RP, suggesting that
our methodology might be suitable for inheritance pat-
terns other than autosomal dominance as well.
Our disease-gene mapping strategies reduced the search
space for causal mutations by ~50% in families with three
affected individuals and by ~95% in families with four
or more affected individuals. Importantly, both of ourrican Journal of Human Genetics 94, 373–384, March 6, 2014 379
Figure 3. Exome-Based Mapping of Genes Associated with
Dominant Disease
(A) Visual depiction of how a disease-causing haplotype (blue)
might segregate with disease status while undergoing recombina-
tion with non-disease-causing haplotypes (white) in a fictitious
dominant pedigree.
(B) Illustration, using haplotypes from the pedigree in (A), of the
methods for disease-gene mapping. Rare variants (gray) segre-
gating on the same haplotype as the disease-causing mutation
(black) will be heterozygous in all affected individuals. In contrast,
homozygous differences between affected pairs (red) indicate
regions where neither haplotype is shared. Orange lines mark
the boundaries of the disease-causing haplotype inherited by all
affected individuals from a common ancestor.
Table 3. RHRO and SIBD Results Compared to Results of
Traditional Linkage Analysis in Three Families
Family ID Known Linkage RHRO and SIBD
ADRP08 chr19: 44–52 Mb chr19: 45–52 Mb
ADRP16 – chr12: 6–20 Mb
chr15: 60–69 Mb chr15: 61–95 Mb
chr19: 36–56 Mb chr19: 41–55 Mb
– chr22: 19–30 Mb
ADRP23 – chr1: 17–18 Mb
chr2: 105–173 Mb chr2: 99–173 Mb
chr4: 111–159 Mb chr4: 107–160 Mb
– chr5: 151–171 Mb
– chr16: 31–47 Mb
chr18: 62–67 Mb chr18: 57–68 Mb
– chr20: 56–61 Mbapproaches rely on the assumption that affected individ-
uals within a family all inherited the same causal mutation
from a common ancestor. They would thus not be suited
to analyses of unrelated individuals affected by rare syn-
dromes. Our methods require at least two affected individ-
uals in a family, and their power is understandably related
to the number of, and meiotic distance between, affected
individuals included in the analysis. In the most infor-
mative family described here (ADRP08; seven affected
individuals), our methods excluded >99% of the exome
and implicated regions on a single chromosome that
were consistent with traditional linkage analysis for the
extended pedigree.
Importantly, RHRO and SIBD analyses occasionally
yield conflicting results (e.g., chromosome 16 in Figure 4)
because of their underlying algorithms and type of variants
used. SIBD analysis requires common variants whose
genetic-map position can be inferred. As such, it might
miss candidate regions (especially smaller ones) when
such markers are not available. In contrast, because
RHRO analysis prioritizes rare heterozygous variants, it of-
fers a slight advantage to sensitivity but might also nomi-
nate candidate regions in repetitive or low-complexity380 The American Journal of Human Genetics 94, 373–384, March 6sequence (e.g., centromeres) as a result of false-positive
variant calls (apparent heterozygous variants arising from
paralogous sequence alignment).
We have presented two lines of evidence to support the
notion that the RHRO and SIBD methods effectively nar-
row the search for causal mutations. First, in three families,
our mapping approaches recapitulated known linkage
from traditional approaches while nominating additional
candidate regions. Because traditional linkage mapping
used more samples in each of these pedigrees, it is possible
that it excluded some of our additional regions along with
information from the wider pedigree. Alternatively, our
methods might have identified new, smaller candidate
regions that were missed by traditional linkage analysis.
Second, two families both had sufficient sample numbers
for exome-based mapping and a pathogenic variant in a
known RP gene; in both of these families, our mapping
approaches nominated candidate regions overlapping the
causal mutation.
Our methods represent some important advances over
current approaches to exome sequencing analysis in Men-
delian disorders. First, our approach prioritizes candidate
variants rather than progressively filtering them, which
ensures that unexpected observations—such as the pres-
ence of disease-causing mutations in dbSNP—will not
remove them from consideration. Such flexibility is para-
mount as large-scale sequencing efforts continue to catalog
rare variants in human populations; our analysis of known
disease-causing mutations for adRP showed that >30%
were present in dbSNP build 137 (see Figure 1A). Second,
our variant scoring methods incorporate read depth and
allele frequency to address the possibility of missing or
incorrect variant calls. Third, we utilize information about
the disease tissue—specifically, relative gene expression
levels—to help prioritize candidate variants. Finally, our
two complementary mapping methods can reduce the, 2014
Figure 4. Exome-Based Gene Mapping in Family ADRP16
For each chromosome, the RHRO results are on top and the SIBD results are on bottom. For the RHRO approach, the proportion of het-
erozygous affected individuals is plotted by rare-variant position along each chromosome in light blue. Variants not found in the un-
affected control are highlighted in royal blue. Positions of homozygous difference between affected pairs (rule outs) are shown in
red. Candidate regions (yellow) are flanked by rule-out positions or the centromere (black dashed lines). For the SIBD approach, the pro-
portion of affected pairs sharing an IBD segment is plotted in 50 kb windows, and segments shared byR80%of affected pairs (horizontal
blue line) are highlighted in gold.search space for the causal mutation by using only the
exome data and can do so with fewer affected individuals
than are required for traditional linkage analysis. In our
analysis of adRP-affected families, >95% of coding bases
could be excluded when four affected individuals were
sequenced.
It is important to note that the 24 families chosen for
exome sequencing met several criteria. They were part of
a cohort of families with a provisional diagnosis of adRP
or dominant-acting X-linked RP, they had been screened
for common disease-causing mutations, and they had at
least two affected individuals who provided informed con-
sent for whole-exome sequencing. Only unaffected par-
ents of probands (noncarriers) were chosen as controls.
We made several assumptions in the analysis of these fam-
ilies: (1) that a single causal mutation was shared by all
affected individuals, (2) that it mapped to a coding region
sufficiently covered by exome sequencing, and (3) that itThe Amematched our empirical observations of known disease-
causing mutations (rare in populations, protein altering,
and affecting retinally expressed genes). Because RP is
genetically heterogeneous, we could not assume that the
pathogenic mutation was at the same position (or even
in the same gene) in different families. Therefore, we
considered each family as an individual unit both at the
variant-calling and analysis stages.
Although factors such as inaccurate pedigree informa-
tion or unexpected forms of inheritance (e.g., digenic
or autosomal recessive) might hinder our variant prioriti-
zation strategy, its performance in three families affected
by recessive or X-linked RP suggests that it remains
relatively robust to such issues. Nevertheless, causal
mutations that are poorly covered by exome sequencing,
annotated incorrectly, or lie in noncoding regulatory
sequences might receive lower scores under this para-
digm. For some Mendelian-disease-affected pedigrees,rican Journal of Human Genetics 94, 373–384, March 6, 2014 381
Table 4. RHRO and SIBD Results for Families with at Least Three Affected Individuals
Family ID Ethnicity Exomes (No. Affected) Regions No. of Chromosomes Refined CDS (Mb) Refined CDS (%)
ADRP05 white 3 (3) 74 21 16.05 48.43%
ADRP07 white 4 (3) 60 22 15.25 46.03%
ADRP03 white 4 (3) 66 22 14.65 44.21%
ADRP09 white 4 (3) 62 23 14.19 42.81%
ADRP12 white 3 (3) 88 22 12.85 38.79%
ADRP06 Hispanic 3 (3) 51 20 6.90 20.81%
ADRP22 white 4 (3) 34 13 3.47 10.48%
ADRP21 white 4 (3) 31 16 1.80 5.44%
ADRP14 white 3 (3) 61 21 1.18 3.57%
ADRP15 white 5 (4) 28 14 1.34 4.05%
ADRP02 black 5 (5) 9 5 1.74 5.25%
ADRP16 white 7 (5) 14 4 1.15 3.46%
ADRP23 white 8 (6) 7 4 1.02 3.07%
ADRP20 white 6 (6) 6 5 0.42 1.26%
ADRP08 black 8 (7) 2 1 0.21 0.63%
Candidate regions and chromosomes from intersecting RHRO and SIBD regions are shown along with the absolute and proportional size of the refined search
space. The following abbreviation is used: CDS, coding sequence.whole-genome sequencing might ultimately be required
for determining the full extent of sequence variation
shared by affected individuals, including structural and
noncoding variants that remain refractory to detection
by exome sequencing.
Although we showcase our methods primarily on auto-
somal-dominant disease, we expect that they will be useful
for other forms of inheritance (e.g., recessive or X-linked)
as well. Future improvements to MendelScan will accom-
modate recessive disease models (e.g., by prioritizing
homozygous variants and compound heterozygotes) and
regulatory variant annotation information (e.g., ENCODE
annotation data sets) to further empower the search for
genes underlying rare inherited disorders.Supplemental Data
Supplemental Data include two figures and five tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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